In vivo, cardiac-specific knockdown of a target protein, malic enzyme-1, in Rat via adenoviral delivery of DNA for non-native miRNA

Current Gene Therapy

Volumn 12, Issue 6, 2012, Pages 454-462

  O'Donnell, J Michael ^a   Kalichira, Asha ^a   Bi, Jain ^a   Lewandowski, Edward D ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

Author keywords

Gene therapy; Heart; MicroRNA; RNA interference; SiRNA

Indexed keywords

ADENOVIRUS VECTOR; CALSEQUESTRIN; COMPLEMENTARY DNA; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MALATE DEHYDROGENASE (DECARBOXYLATING); MALATE DEHYDROGENASE (DECARBOXYLATING) 1; MICRORNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHEMOLUMINESCENCE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DENSITOMETRY; GENE REPRESSION; GENE SILENCING; HEART MUSCLE CELL; MALE; NEWBORN; NONHUMAN; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRAL GENE DELIVERY SYSTEM; WESTERN BLOTTING;

ADENOVIRIDAE; ANIMALS; ANIMALS, NEWBORN; CALSEQUESTRIN; CARDIAC CATHETERIZATION; DNA, COMPLEMENTARY; GENE KNOCKDOWN TECHNIQUES; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE (PHOSPHORYLATING); HEK293 CELLS; HUMANS; MALATE DEHYDROGENASE; MALE; MICRORNAS; MITOCHONDRIA; MYOCARDIAL REPERFUSION; MYOCARDIUM; MYOCYTES, CARDIAC; PROTEIN BIOSYNTHESIS; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; TRANSFECTION;

RATTUS;

EID: 84870230289     PISSN: 15665232     EISSN: 18755631     Source Type: Journal    
DOI: 10.2174/156652312803519760     Document Type: Article

References (40)

1. Gray SJ, Samulski RJ. Optimizing gene delivery vectors for the treatment of heart disease. Expert Opin Biol Ther 2008; 8(7): 911-22.
2. Muller OJ, Katus HA, Bekeredjian R. Targeting the heart with gene therapy-optimized gene delivery methods. Cardiovasc Res 2007; 73(3): 453-62.
3. Poller W, Fechner H. Development of novel cardiovascular therapeutics from small regulatory RNA molecules-an outline of key requirements. Curr Pharm Des 2010; 16(20): 2252-68.
4. Du J, Gao S, Lou J, Zhang G, Cong G, Shao J, et al. Effective inhibition of foot-and-mouth disease virus (FMDV) replication in vitro by vector-delivered microRNAs targeting the 3D gene. Virol J 2011; 8: 292-303.
5. Lv Z, Xu L. Salvianolic acid B inhibits ERK and p38 MAPK signaling in TGF-b1-stimulated human hepatic stellate cell line (LX- 2) via distinct pathways. Evid Based Complement Alternat Med 2012: 2012; 960128.
6. Wittchen ES, Aghajanian A, Burridge K. Isoform-specific difference between Rap1A and Rap1b GTPases in the formation of endothelial cell junctions. Small GTPases 2011; 2(2): 65-76.
7. Brown LJ, Longacre MJ, Hasan NM, Kendrick MA, Stoker SW, Macdonald MJ. Chronic reduction of the cytosolic or mitochondrial NAD(P)-malic enzyme does not affect insulin secretion in a rat insulinoma cell line. J Biol Chem 2009; 284(51): 35359-35367.
8. Pongratz RL, Kibbey RG, Cline GW. Investigating the roles of mitochondrial and cytosolic malic enzyme in inulin secretion. Methods Enzymol 2009; 457: 425-50.
9. Ronnebaum SM, Jensen MV, Hohmeier HE, Burgess SC, Zhou YP, Qian S, et al. Silencing of cytosolic or mitochondrial isoforms of malic enzyme has no effect on glucose-stimulated insulin secretion from rodent islets. J Biol Chem 2008; 283(43); 28909-28917.
10. Gupta S, Maitra R, Young D, Gupta A, Sen S. Silencing the myotrophin gene by RNA interference leads to the regression of cardiac hypertrophy. Am J Physiol Heart Circ Physiol 2009; 297: H627-H636.
11. Huang M, Wu JC. Molecular imaging of RNA interference therapy targeting PDH2 for treatment of myocardial ischemia. Methods Mol Biol 2011; 709: 211-21.
12. Huang M, Chan DA, Jia F, Xie X, Li Z, Hoyt G, et al. Short hairpin RNA interference therapy for ischemic heart disease. Circulation 2008; 118(suppl 1): S226-S233.
13. Morgan PE, Correa MV, Ennis IE, Diez AA, Perez NG, Cingolani HE. Silencing of sodium/hydrogen exchanger in the heart by direct injection of naked siRNA. J Appl Physiol 2011; 111: 566-72.
14. Poller W, Hajjar R, Schultheiss HP, Fechner H. Cardiac-targeted delivery of regulatory RNA molecules and genes for the treatment of heart failure. Cardiovasc Res 2010; 86: 353-64.
15. Lebbink RJ. Lowe M, Chan T, Khine H, Wang X, McManus MT. Polymerase II promoter strength determines efficacy of microRNA adapted shRNAs. PLoS ONE 2011; 6(10): e26213.
16. McBride JL, Boudreau RL, Harper SQ, Staber PD, Monteys AM, Martins I, et al. Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. PNAS 2008; 105(15): 5868-5873.
17. Carthew RW, Sontheimer EJ. Origins and mechanisms of miRNAs and siRNAs. Cell 2009; 136: 642-55.
18. Pushparaj PN, Arthi JJ, Manikandan J, and Kumar SD. siRNA, miRNA, and shRNA: in vivo application. J Dent Res 2008; 87(11): 992-1003.
19. Rao DD, Vorhies JS, Senzer N, Nemunaitis J. siRNA vs shRNA similarities and differences. Adv Drug Del Rev 2009; 61: 746-759.
20. Bushati N, Cohen SM. microRNA Functions. Annu Rev Cell Dev Biol 2007; 23:175-205.
21. O'Donnell JM, ED Lewandowski. Efficient, Cardiac-Specific Adenoviral Gene Transfer by Isolated Retrograde Perfusion In Vivo. Gene Ther 2005; 12: 958-64.
22. O'Donnell JM, ED Lewandowski. Controlling specificity and efficiency of adenoviral gene transfer in heart by catheter based coronary perfusion. In: Gene Therapy Prospective assessment in its societal context. Niewohner J. & Tannert C. (Eds), Amsterdam, Netherlands, Elsevier (pub) 2006, Pp 33-46.
23. O'Donnell JM, Fields AD, Xu X, Chowdhury SA, Geenen DL, Bi J. Limited functional and metabolic improvements in hypertrophic and healthy hearts expressing the skeletal muscle isoform of SERCA1 by adenoviral gene transfer in vivo. Amer J Physiol (Heart and Circ) 2008; 295(6): H2483-94.
24. O'Donnell JM, Pound K., Xu X, Lewandowski ED. SERCA1 Expression enhances the metabolic efficiency of improved contractility in post ischemic hearts. J Mol Cell Cardio 2009; 47(5): 614-21.
25. Pound KM, Sorokina N, Ballal K, Berkich DA, Fasano M, LaNoue KF, et al. Substrate-enzyme competition attenuates upregulated anaplerotic flux through malic enzyme in hypertrophied hearts and restores triacylglyceride content: attenuating upregulated anaplerosis in hypertrophy. Circulation Research 2009; 104(6): 805-12.
26. Sorokina N, O'Donnell JM, McKinney RD, Pound KM, Woldegiorgis G, LaNoue KF, et al. Recruitment of compensatory pathways to sustain oxidative flux with reduced carnitine palmitoyltransferase I activity characterizes inefficiency in energy metabolism in hypertrophied hearts. Circulation 2007; 155(15): 2033-41.
27. Cavagna M, O'Donnell JM, Sumbilla C, Inesi G, Klein MG. Exogenous Ca2+-ATPase isoform effects on Ca2+ transients of embryonic chicken and neonatal rat cardiac myocytes. J Physiol 2000; 528: 53-63.
28. Suckau L, Fechner H, Chemaly E, Krohn S, Hadri L, Kockskämper J, et al. Long-term cardiac-targeted RNA interference for the treatment of heart failure restores cardiac function and reduces pathological hypertrophy. Circulation 2009; 119: 1241-1252.
29. Weisser-Thomas J, Dietrich E, Janssen PML, Schmidt-Schwead S, Maier LS, Sumbilla C, et al. Method-related effects of adenovirusmediated LacZ and SERCA1 gene transfer on contractile behavior of cultured failing human cardiomyocytes. J Pharm Tox Meth 2005; 51: 91-103.
30. Lorio MV, Casalini P, Piovan C, Di Leva G, Merlo A, Triulzi T, et al. microRNA-205 regulates HER3 in human breast cancer. Cancer Res 2009; 69: 2195-2200.
31. Taulli R, Bersani F, Foglizo V, Linari A, Bigna E, Ladanyi M, et al. The muscle-specific microRNA miR-206 blocks human rhabdomyosarcoma growth in xenotranspolanted mice by promoting myogenic differentiation. J Clin Invest 2009; 119: 2366-2378.
32. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116(2): 281-97.
33. Griffin JL, O'Donnell JM, White LT, Hajjar RJ, Lewandowski ED. Postnatal expression and activity of the mitochondrial 2- oxoglutarate-malate carrier in intact hearts. Am J Physiol Cell Physiol 2000; 279(6): C1704-1709.
34. Lewandowski ED, O'Donnell JM, Scholz TD, Sorokina N, Buttrick PM. Recruitment of NADH shuttling in pressure-overloaded and hypertrophic rat hearts. Am J Physiol Cell Physiol 2007; 292(5): C1880-1886.
35. Mayra A, Tomimitsu H, Kubodera T, Kobayashi M, Piao W, Sunaga F, et al. Intraperitoneal AAV9-shRNA inhibits target expression in neonatal skeletal and cardiac muscles. Biochem Biophys Res Commun 2011; 405(2): 204-9.
36. Prasad KM, Xu Y, Yang Z, Acton ST, French BA. Robust cardiomyocyte- specific gene expression following systemic injection of AAV: In vivo gene delivery follows a poisson distribution. Gene Ther 2011; 19(1): 43-52.
37. Grimm D, Streetz KL, Jopling CL, Storm TA, Pandey K, Davis CR, et al. Fatality in mice due to oversaturation of cellular microRNA/ short hairpin RNA pathways. Nature 2006; 441: 537-41.
38. Hajjar RJ, Schmidt U, Matsui T, Guerrero JL, Lee Kyung-Han, Gwathmey JK, et al. Modulation of ventricular function through gene transfer in vivo. PNAS 1998; 95: 5251-5256.
39. Ahi YS, Bangari DS, Mittal SK. Adenoviral Vector Immunity: Its Implications and Circumvention Strategies. Curr Gene Ther 2011; 11(4): 307-20.
40. Reeti KR, Chen CY, Weaver EA, Barry MA. Advances and Future Challenges in Adenoviral Vector Pharmacology and Targeting. Curr Gene Ther 2011; 11(4): 241-58.